The materials on this website are intended for the use of Roche's shareholders, employees and other constituencies. They are not an offer to purchase, or a solicitation of an offer to sell, any securities of Genentech or a solicitation of proxies or consents from any shareholder of Genentech.
In the event a transaction is approved by the independent directors of Genentech and submitted to a vote of Genentech shareholders, Genentech would file proxy and other materials with the U.S. Securities and Exchange Commission. These materials would contain important information regarding the transaction.
This site contains certain forward-looking statements. These forward-looking statements may be identified by words such as "believes", "expects", "anticipates", "projects", "intends", "should", "seeks", "estimates", "future" or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, including among others:
- pricing and product initiatives of competitors;
- legislative and regulatory developments and economic conditions;
- delay or inability in obtaining regulatory approvals or bringing products
to market;
- developments in financial market conditions, including the market
for acquisition financing and other capital markets and fluctuations
in currency exchange rates;
- uncertainties in the discovery, development or marketing of new products
or new uses of existing products, including without limitation negative
results of clinical trials or research projects and unexpected side-effects
of pipeline or marketed products;
- increased government pricing pressures or changes in third party reimbursement
rates;
- interruptions in production;
- loss of or inability to obtain adequate protection for intellectual
property rights;
- Litigation;
- the inherent uncertainties involved in negotiations with the special
committee of Genentech and that there can be no assurances that a negotiated
transaction will ultimately be agreed to or consummated;
- potential difficulties in integrating the businesses of Genentech
and Roche, and that some or all of the anticipated benefits of the proposed
transaction may not be realized on the schedule contemplated or at all;
- that future dividends are subject to the discretion of the board of
directors of Roche and a number of other factors, some of which are
beyond the control of Roche;
- the ability of Roche to generate cash flow to, among other things,
repay acquisition-related debt as currently contemplated;
- loss of key executives or other employees; and
- adverse publicity and news coverage.
The directors of Genentech who are also employees of Roche will not take part in the consideration of the proposed transaction by the Genentech board and accordingly are not permitted to comment or respond to questions regarding the transaction as representatives of Genentech.
For marketed products discussed in this site, please see full prescribing information on our website - www.roche.com. All mentioned trademarks are legally protected.
